Logo

Broad Institute to Use Affy s 500K Arrays in Large-Scale Genotyping Study

Jul 21, 2005

NEW YORK, July 21 (GenomeWeb News) - The Broad Institute will use Affymetrix's genotyping arrays to conduct whole-genome association studies looking into the genetic causes of cancer, cardiovascular, metabolic, and neuropsychiatric diseases, the company said today.

 

Institute researchers and their collaborators in academia and industry plan to use Affy's GeneChip Mapping 500K arrays to analyze 12,000 human DNA samples, generating more than 6 billion genotypes. They also plan to develop new laboratory and analysis methods for the arrays, which they will use under an early access program.

 

Affymetrix said it expects to launch the 500K arrays commercially later this year.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.